

AMENDMENTS TO THE CLAIMS

1. (previously presented): A method for reducing scarring during the healing of wounds, reducing fibrosis in the treatment of fibrotic conditions, or for preventing or inhibiting scar formation or fibrosis, comprising applying a furin inhibitor to a site of a wound or fibrotic disorder or to a site where a wound may form or fibrosis may occur.
2. (previously presented): The method defined in claim 1 wherein the inhibitor is a serine protease inhibitor.
3. (previously presented): The method defined in claim 1 wherein the inhibitor is lipid soluble.
4. (previously presented): The method defined in claim 2 wherein the inhibitor is a peptidyl chloroalkylketone having a peptide moiety which mimics at least one convertase enzyme cleavage site.
5. (currently ammended): The method defined in claim 2 wherein the inhibitor is decanoyl-RVKR-cmk (SEQ ID NO:1).
6. (previously presented): The method defined in claim 1 wherein the inhibitor is water soluble.
7. (previously presented): The method defined in claim 6 wherein the inhibitor is hexa-arginine.
8. (previously presented): The method defined in claim 15 for treating wounds to inhibit or prevent scar formation.

9. (previously presented): The method defined in claim 8 for inhibiting or preventing scarring of the eye, nervous tissue or intestines.
10. (previously presented): The method defined in claim 8 for inhibiting or preventing dermal scarring.
11. (previously presented): The method defined in claim 8 for inhibiting or preventing scarring following a burn.
12. (previously presented): The method defined in claim 1 for reducing fibrosis in the treatment of fibrotic conditions.
13. (previously presented): The method defined in claim 12 wherein the fibrotic condition is a fibrotic disorder selected from glomerulonephritis, cirrhosis of the liver, fibrocytic disease, adhesions or restenosis.
14. (previously presented): A composition comprising an effective amount of a furin inhibitor for reducing scarring during the healing of wounds, reducing fibrosis in the treatment of fibrotic conditions, or for preventing scar formation or fibrosis, and a pharmaceutically acceptable carrier.
15. (previously presented): A method of inhibiting the generation of TGF- β 1 comprising applying a furin inhibitor to a site where TGF- β 1 is generated.
16. (previously presented): A method of claim 15 wherein said site is a site of platelet activation.
17. (previously presented): A composition comprising a TGF- β 1 generation inhibiting effective amount of a furin inhibitor and a pharmaceutically acceptable carrier.